America is confronting an opioid crisis of unprecedented proportions, starkly highlighted by the devastating impact of fentanyl — a synthetic opioid 50 times more potent than heroin. According to the latest data from the CDC, more than 112,000 Americans died from drug overdoses in 2023, with fentanyl being the leading cause. This staggering death toll surpasses U.S. military casualties in Vietnam, Iraq, and Afghanistan combined, signaling a national emergency that demands immediate attention.
While these numbers are staggering, they only scratch the surface of a deeper problem: our society's heavy reliance on narcotics for managing pain and the alarming lack of safe, non-narcotic alternatives. The crisis is not confined to any single demographic — it affects people from all walks of life, ages, and backgrounds.
Fentanyl has become the leading cause of death among Americans 18 to 45 years old. Many young adults unknowingly consume counterfeit pills laced with fentanyl, believing they are taking prescription medications like Xanax or Oxycodone. These counterfeit drugs are often indistinguishable from legitimate ones, making the risk of accidental overdose alarmingly high.
Families across the nation are grappling with unimaginable loss. Parents who thought their children were making typical youthful mistakes are now burying them because of one irreversible decision. This pervasive reach underscores the urgent need to address the root causes of the epidemic.
Understanding the current crisis requires recognizing how tightly intertwined opioid use is with pain management. The National Institute on Drug Abuse confirms that 21%–29% of patients prescribed opioids for chronic pain misuse them, and 8%–12% develop an opioid use disorder. This trajectory often leads to illicit drug use, including fentanyl, either knowingly or unknowingly.
The underlying issue is that our health care system often leaves patients with few effective alternatives for pain relief. For decades, opioids have been the default solution for chronic pain despite their high potential for addiction and abuse. When legitimate prescriptions run out or become too expensive, patients may turn to the black market, where counterfeit pills laced with fentanyl are prevalent. This lack of accessible, effective, non-opioid pain therapies directly contributes to the proliferation of fentanyl use and the ensuing fatalities.
Addressing the root cause calls for innovation in pain management. Yet, investment and interest in pain therapeutics are plummeting. A 2023 Biotechnology Innovation Organization report revealed that clinical pain drug programs dropped by 44% between 2018 and 2023. The private sector's disinterest is stark; only 1.3% of venture capital in therapeutics was allocated to pain and addiction in 2021, compared to the $9.7 billion funneled into oncology.
Several factors contribute to this decline. Previous pain programs often lacked solid scientific foundations, and clinical trials employed suboptimal models, leading to disappointing results. Additionally, policy decisions like the Inflation Reduction Act inadvertently stifle innovation by favoring biologics over more affordable small-molecule drugs, where 85% of pain program innovation lies. This legislative environment could be the death of small-molecule-based drug development, further limiting non-opioid treatment options.
The lack of investment in innovative, non-opioid pain therapies means patients continue to rely on opioids, perpetuating the cycle of addiction. Without new, effective pain management solutions, the demand for opioids remains high, providing fertile ground for the illegal fentanyl market to thrive.
Pain is a global juggernaut of suffering, affecting 27% of adults worldwide. In the U.S., more than 50 million people grapple with chronic pain daily. The associated health care costs are astronomical — exceeding $635B annually, more than the combined costs for diabetes and cancer. Beyond the financial burden, chronic pain diminishes quality of life, hinders productivity, and fuels the ongoing opioid and fentanyl crisis.
Our current path is both financially and morally untenable. Continuing to rely on opioids without investing in alternative therapies perpetuates a cycle of addiction and death. The absence of effective non-opioid pain treatments leaves patients vulnerable to the risks associated with opioid use, including the possibility of encountering fentanyl-laced substances.
A Call to Action
America can and must do better. We need a multi-pronged strategy combining innovation, investment, and public health policy to break the cycle linking pain management and the fentanyl crisis.
- Invest in Research: Academic institutions must spearhead the development of novel pain therapies grounded in solid scientific research. This includes exploring non-opioid medications, alternative delivery systems, and multidisciplinary approaches to pain management. Strategic partnerships between academia and the pharmaceutical industry can bridge the gap between discovery and delivery, accelerating the development of effective treatments.
- Encourage Private Sector Engagement: Venture capital firms and investors must recognize the critical need for innovation in pain management and allocate resources accordingly. By investing in non-opioid pain therapies, the private sector can play a crucial role in reducing the nation's reliance on opioids and, by extension, the demand for illicit fentanyl.
- Policy Reforms: Policymakers must ensure regulations like the Inflation Reduction Act do not inadvertently stifle innovation. Legislative adjustments are necessary to create a balanced environment that encourages the development of affordable small-molecule drugs alongside biologics. Regulatory frameworks should balance safety with the urgency of addressing a public health crisis.
- Public Awareness and Education: There is a dire need for public education on the dangers of counterfeit pills and the prevalence of fentanyl in street drugs. Parents, educators, clinicians, and community leaders must collaborate to spread awareness. Early intervention programs and educational campaigns can equip individuals with the knowledge to make safer choices.
Our nation faces a moment of reckoning. The fentanyl and opioid crisis isn't just a series of statistics; it's a tapestry of human suffering that traces back to how we manage pain. The lack of effective, non-opioid pain therapies has left a void that opioids — and by extension, illicit substances like fentanyl — have filled. Without immediate action, we risk losing an entire generation to preventable deaths.
We have the knowledge and resources to change course. Investing in innovative pain management is not just an option; it's a necessity for the nation's well-being. By developing and providing access to effective non-opioid pain treatments, we can reduce the demand for opioids, disrupt the cycle of addiction, and combat the fentanyl crisis head-on.
The question is, will we rise to the occasion?
Dr. Hernan Bazan is The John Ochsner Professor of Cardiovascular Innovation and Surgery at Ochsner Health in New Orleans, LA, and the recipient of the 2024 NIH HEAL Initiative Director’s Trailblazer Award. He specializes in vascular surgery and non-opioid pain therapy research and clinical development.
Image by Alphavector / Shutterstock
